ReviewFrontiers in endocrinology2026
The effect of combining surgical or endoscopic bariatric interventions with anti-obesity medication or probiotics on weight loss: a narrative review.
Review in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity is a multifactorial chronic disease associated with multiple health complications. While bariatric surgery and endoscopic sleeve gastroplasty (ESG) are effective treatments for severe obesity, patients may still experience challenges such as weight regain or inadequate weight loss. As a result, combining these interventions with adjunctive treatment such as anti-obesity medication (AOM) or probiotics has become an area of increasing clinical interest. This narrative review summarizes the current evidence on the effect of combining surgical or endoscopic bariatric interventions with AOM or probiotics. Available studies suggest that the combination of GLP-1 receptor agonists (GLP-1 RA) and ESG leads to more weight loss than ESG alone. In contrast, non-GLP-1 RA medication show less consistent benefits and generally lower weight loss. GLP-1 RAs and tirzepatide show clinically relevant short term weight loss in patients with weight regain or insufficient weight loss after bariatric surgery. Other AOM, such as topiramate, phentermine, orlistat and bupropion/naltrexone result in more modest and variable outcomes. Relatively small studies on probiotics and prebiotics in combination with bariatric surgery do not find a statistically significant difference in weight loss between probiotic and placebo groups. Although small benefits in waist circumference, liver enzymes and vitamin uptake are mentioned, the effects are modest and not consistent across studies. In conclusion, combining AOM, especially GLP-1 RAs, with surgical or endoscopic obesity treatments appears to enhance weight loss in patients with suboptimal outcomes. These findings support the use of AOM as an adjunct to bariatric procedures. In addition, additional adequately powered studies are needed to evaluate the role for probiotics in improving weight loss after bariatric surgery. Future research should focus on long-term outcomes, side effects, and identifying patient subgroups that may benefit most from combined therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.